

Peer Reviewed

1. **Agus DB**, Mann R, Cohn D, Kelly C, Clayman M, Neilson E: Inhibitory role of dietary protein restriction on development and expression of immune-mediated anti-tubular basement membrane disease producing tubulointerstitial nephritis in rats. *J Clin Invest* 76:930-936, 1985.
2. **Agus DB**, Mann R, Clayman M, Kelly C, Michaud L, Cohn D, Neilson EG: The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats. *Kidney Internatl* 29:635-640, 1986.
3. **Agus DB**, Suhr C, Sprent J: Re-entry of T cells to the adult thymus is restricted to activated T cells. *J Exp Med* 173:1039-1046, 1991.
4. Deguchi Y, **Agus D**, Kehrl JH: A human homeobox gene, HB24, inhibits development of CD4+ T cells and impairs thymic involution in transgenic mice. *J Biol Chem* 268:3646-3653, 1993.
5. Sprent J, Surh C, **Agus D**, Hurd M, Sutton S: Profound atrophy of bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4 cells. *J Exp Med* 180: 307-317, 1994.
6. Kothari PJ, Finn RD, Bornmann WG, **Agus DB**, Vera JC, Larson SM: Chemical consequences resulting from multi-millicurie preparation of 6-[18F]-fluoro-6-deoxy-L-ascorbic acid. *Radiochimica Acta* 77:87-90, 1997.
7. **Agus DB**, Gambhir SS, Pardridge W, Spielholz C, Baselga J, Vera J, Golde DW: Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters, *J Clin Invest* 100(11):2842-2848, 1997.
8. Stearns ME, Ware JL, **Agus DB**, Chang C, Fidler J, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG, Thalmann GN: Human xenograft models of prostate cancer. *Prostate* 36:56-58, 1998.
9. **Agus DB**, Golde D, Sgouros G, Cordon-Cardo C, Scher H: Positron emission tomography of human prostate cancer xenograft: association of changes in deoxyglucose accumulation and response to hormonal therapy. *Cancer Res* 58(14): 3009-3014, 1998.
10. **Agus DB**, Vera J, Golde D: Stromal cell oxidation: A mechanism by which tumors obtain vitamin C. *Cancer Res* 59(18):4555-4558, 1999.
11. **Agus DB**, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW: Response of prostate cancer to anti-Her-2/neu antibody in androgen dependent and independent human xenograft models. *Cancer Res* 59(19):4761-4764, 1999.
12. **Agus D**, Scher H, Fox W, Drobnjak M, Koff A, Golde D, Cordon-Cardo C: Alterations of cell cycle regulators in prostate cancer: response to androgen

- withdrawal and development of androgen independence. *J Natl Cancer Inst* 91(21):1869-1876, 1999.
13. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, **Agus DB**, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD: Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. *J Clin Onc* 17(12):3776-3785, 1999.
 14. **Agus DB**, Amler LC, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. *Cancer Res* 60(21):6134-6141, 2000.
 15. McDonald S, Brive L, **Agus D**, Scher H, Ely K: Ligand responsiveness in prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. *Cancer Res* 60:2317-2322, 2000.
 16. **Agus DB**, Bunn PA, Franklin W, Garcia M, Ozols RF: Her-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. *Seminars Oncol* 27(6):53-63, 2000.
 17. **Agus DB**, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX: A potential role for activated HER-2 in prostate cancer. *Seminars Oncol* 27(6):76-83, 2000.
 18. **Agus DB**: Case study in lymphoma: a patient with chemotherapy refractory lymphoma treated with rituximab and chemotherapy. *Biol Ther Lymphoma* 3(3):5-6, 2000.
 19. Butler DB, **Agus DB**, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoyanilide hydroxamic acid (SAHA), an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. *Cancer Res* 60(18):5165-5170, 2000.
 20. Treon SP, **Agus DB**, Link B, Rodrigues G, Molina A, lAcy MQ, Fisher DC, Emmanouilides C, Richards AI, Richon VM: Suberoyanilide hydroxamic acid (SAHA), an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. *Cancer Res* 24(3):272-279, 2000.
 21. Huang J, **Agus DB**, Winfree C, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES: Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. *Proc Natl Acad Sci USA* 98:11720-11724, 2001.

22. Brive L, **Agus DB**, Ely KR: Structure-based androgen receptor gene mutation database: a tool to link molecular location and clinical phenotype. *Prostate J* 3(2):76-91, 2001.
23. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, **Agus D**, Ross JS, Cordon-Cardo C: Her-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. *Clin Cancer Res* 7(9):2643-2647, 2001.
24. Butler LM, Webb Y, **Agus DB**, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. *Clin Cancer Res* 7(4):962-970, 2001.
25. Roberts WK, Livingston PO, **Agus DB**, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA: Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. *Blood* 99(10):3748-3755, 2002.
26. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, **Agus DB**, Scher HI, Rosen N: 17-allyl-aminogeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. *Clin Cancer Res* 8(5):986-993, 2002.
27. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, **Agus DB**: Antibody to VEGF slows growth of an androgen independent xenograft model of prostate cancer. *Clin Cancer Res* 8(10):3226-3231, 2002.
28. **Agus DB**, Akita RW, Fox WD, Tindell C, Higgins B, Lewis GD, Maiese K, Pisacane PI, Lofgren JA, Evans D, Scher HI, Sliwkowski MX: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. *Cancer Cell* 2:127-137, 2002.
29. Gery S, Sawyers CL, **Agus DB**, Said JW, Koeffler HP: TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. *Oncogene* 21(31):4739-4746, 2002.
30. **Agus DB**, Akita RW, Fox WD, Tindell C, Higgins B, Lewis GD, Maiese K, Piscane PI, Lofgren JA, Evans D, Scher HI, Sliwkowski MX: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. *Cancer Cell* 2:127-137, 2002.
31. Bonham MJ, Galkin A, Montgomery B, Stahl WL, **Agus D**, Nelson PS: Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. *J Nat Cancer Inst* 94(21):1641-1647, 2002.
32. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiyah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Tricker PD, Scher HI, Grygiel JJ, **Agus**

- DB**, Mack DH, Sutherland RL: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. *Cancer Res* 63(14):4196-4203, 2003.
33. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Fox W, **Agus DB**: Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. *Cancer Cell* 5(6):565-574, 2004.
34. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, **Agus D**, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group. *J Clin Oncol* 22(3):537-556, 2004.
35. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, **Agus DB**: CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. *Prostate* 61(3):228-235, 2004.
36. **Agus DB**, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe Gz: A phase I clinical study of pertuzumab (recombinant humanized monoclonal antibody 2C4), a novel her dimerization inhibitor (HDI), in patients with advanced cancer. *J Clin Onc* 23(11):2534-2543, 2005.
37. Jain A, Tindell C, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, **Agus DB**: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. *Proc Natl Acad Sci USA* 102(33):11858-11863, 2005.
38. Shazer RL, Jain A, Galkin AV, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, **Agus DB**: Raloxifene, an ER- β targeted therapy, inhibits androgen independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. *Br J Urol* 97(4):691-697, 2006.
39. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, **Agus DB**, Koeffler HP: 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. *Cancer* 104(12):2701-2708, 2005.
40. Laux I, Jain A, Singh S, **Agus DB**: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. *Br J Cancer* 94(1):85-92, 2006.
41. **Agus D**, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison D, Kattan MW, Scher HI: Efficacy and safety of single-agent pertuzumab, a HER dimerization inhibitor in castration-

- resistant prostate cancer after progression from taxane-based therapy. *J Clin Onc* 25(6):675-681, 2007.
42. Dreicer R, Petrylak D, **Agus D**, Wbb I, Roth B: Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. *Clin Cancer Research* 13(4):1208-1215, 2007.
 43. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, **Agus DB**: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. *BMC Cancer* 7:142-147, 2007.
 44. Kessner D, Chambers M, Burke R, **Agus D** and Mallick P. ProteoWizard: open source software for rapid proteomics tools development. *Bioinformatics* 24(21):2534-2536, 2008.
 45. Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, **Agus DB**, Mallick P: Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. *J Proteome Res* 7(9):4031-4039, 2008.
 46. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, **Agus DB**: Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. *Psychooncology* 18(5):508-514, 2009.
 47. Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, **Agus DB**, Cristini V: Multiparameter computational modeling of tumor invasion. *Cancer Res* 69(10):4493-4501, 2009.
 48. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, **Agus DB**, Jain A: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. *Mol Cancer Ther* 8:2882-2893, 2009.
 49. Smith MR, **Agus D**, et al.: Denosumab HALT Prostrate Cancer Study Group: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 361:745-755, 2009.
 50. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, **Agus DB**: HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. *Cancer Res* 70:1989-1999, 2010.
 51. Jiang Y, Palma JF, **Agus DB**, Wang Y, Gross ME: Detection of androgen receptor mutation in circulating tumor cells in castration-resistant prostate cancer. *Clin Chem* 56:1492-1495, 2010. Epub 2010 Jun 25.

52. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, **Agus DB**, Pienta KJ, Carpten JD: Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. *Genome Res* 21:47-55, 2011. Epub 2010 Dec 8.
53. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, **Agus DB**, Cooney K, Chen A, Smith DC, Hussain M: Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration-resistant prostate cancer, NCI-6735: a study by the DOD/PCF prostate cancer clinical trials consortium. *Invest New Drugs*, in press, 2010. Epub ahead of print.
54. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, **Agus DB**, Mallick P. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. *Mol Cancer Ther.* 2012 May;11(5):1071-81. Epub 2012 Mar 12.
55. Gross ME, Leichman L, Lowe ES, Swaisland A, **Agus DB**: Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. *Cancer Chemother Pharmacol.* 2012 Jan;69(1):273-80. Epub 2011 Oct 15.
56. Mumenthaler SM, Foo J, Leder K, Choi NC, **Agus DB**, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. *Mol Pharm.* 2011 Dec 5;8(6):2069-79. Epub 2011 Oct 25.
57. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, **Agus DB**, McIntosh MW, Mallick P. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. *PLoS One.* 2011;6(7):e23090. Epub 2011 Jul 29.
58. **Agus DB**, et al: A physical sciences network characterization of non-tumorigenic and metastatic cells. *Sci Rep.* 2013;3:1449. doi: 10.1038/srep01449.
59. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, **Agus DB**: A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. *Invest New Drugs.* Apr;31(2):409-16. doi: 10.1007/s10637-012-9904-9, 2013.
60. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N,

- Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, **Agus DB**, MacCoss M, Tabb DL, Mallick P: A cross-platform toolkit for mass spectrometry and proteomics. *Nat Biotechnol.* Oct;30(10):918-20, 2012.
61. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, **Agus DB**, Mallick P, Gross ME: Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. *Prostate.* Feb 15;73(3):306-15. doi: 10.1002/pros.22569, 2013.
 62. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, **Agus DB**: Body image predicts quality of life in men with prostate cancer. *Psychooncology.* Apr;22(4):756-61. doi: 10.1002/pon.3063, 2013.
 63. Dreicer R1, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, **Agus DB**. Phase I/II trial of orteronel (TAK-700)- an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. *Clin Cancer Res.* 2014 Mar 1;20(5):1335-44.
 64. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, **Agus D**, Bellmunt J, Petrylak DP, Lee S-Y, Webb IJ, Tejura B, Borgstein N, and Dreicer R. Phase III, Randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. *J Clin Oncol.* 2015 Mar 1;33(7):723-31 Epub Jan 26.2105.
 65. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, **Agus DB**, Pao W, Michor F, Mallick P. The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells. *Cancer Inform.* 2015 Jul 15;14(Suppl 4):19-31. doi: 10.4137/CIN.S19338. eCollection 2015.
 66. Hsu CY, Ballard S, Battle D, Bonventre JV, Böttinger EP, Feldman HI, Klein JB, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasani RS, Waikar SS, Whitehead KM, Nelson RG; CKD biomarkers consortium. Cross-disciplinary biomarkers research: lessons learned by the CKD biomarkers consortium. *Clin J Am Soc Nephrol.* 2015 May 7;10(5):894-902.
 67. Eisenberg SA, Kurita K, Taylor-Ford M, **Agus DB**, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in

- prostate cancer survivors. *Psychooncology*. 2015 Feb;24(2):228-35. doi: 10.1002/pon.3590. Epub 2014 Jun 2. PMID: 24891013
68. Chiu CL, Patsch K, Cutrale F, Soundararajan A, **Agus DB**, Fraser SE, Ruderman D. Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). *Sci Rep*. 2016 Mar 3;6:22435. doi: 10.1038/srep22435.
 69. Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, **Agus DB**, Mallick P, Foo J, and Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. *Sci Rep*. 2016 Jul 25;6:29752. doi: 10.1038/srep29752.
 70. Jones JJ, Wilcox BE, Benz RW, Babbar N, Boragine G, Burrell T, Christie EB, Croner LJ, Cun P, Dillon R, Kairs SN, Kao A, Preston R, Schreckengaust SR, Skor H, Smith WF, You J, Hillis WD, **Agus DB**, and Blume JE. A plasma-based protein marker panel for colorectal cancer detection identified by multiplex targeted mass spectrometry. *Clin Colorectal Cancer*. 2016 Jun;15(2):186-194.e13. doi: 10.1016/j.clcc.2016.02.004. Epub 2016 Mar 25.
 71. Patsch K, Chiu CL, Engeln M, **Agus DB**, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. *Sci Rep*. 2016 Oct 6;6:34785. doi: 10.1038/srep34785.
 72. Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, **Agus DB**, Mumenthaler SM, Macklin P. Quantifying differences in cell line population dynamics using CellPD. *BMC Syst Biol*. 2016 Sep 21;10(1):92.
 73. **Agus DB**, Gaudette É, Goldman DP, and Messali A. The long-term benefits of increased aspirin use by at-risk Americans aged 50 and older. *PLoS One*. 2016 Nov 30;11(11):e0166103.
 74. Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, **Agus DB**, Mallick P. JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines. *Mol Cancer Ther*. 2017 May 31. pii: molcanther.0564.2016. doi: 10.1158/1535-7163.MCT-16-0564. [Epub ahead of print]
 75. Fröbert O, Götberg M, Angerås O, Jonasson L, Erlinge D, Engström T, Persson J, Jensen SE, Omerovic E, James SK, Lagerqvist B, Nilsson J, Kåregren A, Moer R, Yang C, **Agus DB**, Erglis A, Jensen LO, Jakobsen L, Christiansen EH, Pernow J. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. *Am Heart J* 2017; 189: 94-

102.

76. Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, **Agus DB**. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). *Clin Genitourin Cancer*. 2017 Jul 14. pii: S1558-7673(17)30200-8. doi: 10.1016/j.clgc.2017.07.003. [Epub ahead of print]
77. Jaffee EM, Dang CV, **Agus DB**, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. *Lancet Oncol*. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. PMID: 29208398
78. Rawat RR, Ruderman D, Macklin P, Rimm DL, **Agus DB**. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. *NPJ Breast Cancer*. 2018 Sep 4;4:32. doi: 10.1038/s41523-018-0084-4. eCollection 2018.

Editorials and Reviews

1. Gross ME, Shazer RL, **Agus DB**: Targeting the HER-kinase axis in cancer. *Seminars Oncol* 31(1 Suppl 3):9-20, 2004.
2. Gross ME, Jo S, **Agus DB**: Update on Her-Kinase-directed therapy in prostate cancer. *Clin Advances Hematol Oncol* 2(1):53-56, 2004.
3. Jain A, **Agus DB**: PPARgamma signaling: one size fits all? *Cell Cycle* 3(11):1352-1354, 2004.
4. Shazer RL, Luthringer D, **Agus DB**, Gross ME: Ductal, adenocarcinoma of the prostate. *Clin Advances Hematol Oncol* 2(6):393-395, 2004.
5. Ettinger DS, Ratain MJ, Cheson BD, Goldberg RM, **Agus DB**: Impressions from ASCO. *Clin Advances Hematol Oncol* 3(6):479-483, 2005.
6. Katz JE, **Agus DB**: Protein profiling of blood in prostate cancer. *Br J Urol* 96(4):477-482, 2005.

7. deVera IE, Katz JE, **Agus DB**: Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. *Clin Advances Hematol Oncol* 4(7): 541-549, 2006.
8. Stephan D, **Agus D**, Nierenberg M, Silver E: Personalized genetics: a responsible approach. *Am J Hum Genet* 83(1):130-131, 2008.
9. Pienta KJ, Abate-Shen C, **Agus DB**, Attar R, Chung LWK, Greenberg N, Hahn WC, Isaacs JT, Navone N, Peehl D, Simons JW, Solit D, Soule H, VanDyke T, Weber MJ, Wu L, Vessella R: The current state of preclinical prostate cancer animal models. *Prostate* 68(6):629-639, 2008.
10. **Agus DB**: Reframe the health debate. *Fortune* 166(7): 22, 2012.
11. **Agus DB**, Michor F. The sciences converge to fight cancer. *Nature Physics* 8(11): 773-4, 2012.
12. **Agus DB**: A doctor in your pocket: what does the future of medicine hold? *The Wall Street Journal*, January 14, 2012.
13. **Agus DB**: Saving Corporate Cash by Hiring a Chief Health Officer. *The Wall Street Journal*, January 14, 2012.
14. **Agus DB**, Gell-Mann M: _Perspective: Meeting of minds. *Nature*. Nov 22; 491(7425): S61, 2012.
15. **Agus DB**: The 2,000-year old wonder drug. *The New York Times*, December 11, 2012.
16. **Agus DB**: The outrageous cost of a gene test. *The New York Times*, May 20, 2013.
17. Dzaou VJ, Ginsburg GS, Van Nuys K, **Agus D**, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. *Lancet* 2015 May 23; 385(9982): 2118-9.
18. Davies PC and **Agus DB**. Stochasticity and determinism in cancer creation and progression. *Converg Sci Phys Oncol*. **1** (2015) 026003.
19. **Agus DB**. The doctor will see you (and your data) now. *Fortune*. 2016 Jan 1;173(1):90-93.
20. **Agus DB**: Give up your data to cure disease. *The New York Times*, February 6, 2016.

21. **Agus DB** and Goldman D: Innovative drugs deserve innovative pricing. *Fortune*. 2017 Aug 31.
22. **Agus DB**, Jaffee E, Simon G, Thiboldeaux K, and Zients J: How We Can Win the War on Cancer. *Fortune*. 2017 Jun 29.

Chapters

1. **Agus DB**, Bell WR: Prevention of venous thrombosis in the surgical patient. In: Current Surgical Therapy (5th edition; Cameron J [editor]). Mosby, Philadelphia, PA, pp780-784, 1995.
2. Simon GC, **Agus DB**, Hanna MS: Using electronic medical records to bridge patient care and research in oncology. In: ASCO Educational Book 2006.
3. Jain A, Shazer R, Laux I, **Agus DB**: HER-2/neu and anti-HER-2/neu therapies in prostate cancer. In: The Molecular Oncology of Prostate Cancer (1st edition; Ross JS, Cordon-Cardo C, Foster CS, Scardino PT [editors]). Jones and Bartlett, Sudbury, MA, 2006.
4. Jain A, **Agus D**: Models for prostate cancer. In: The Cancer Handbook (2nd edition; Alison MR [editor]). John Wiley & Sons, Ltd, West Sussex, UK, pp1083-1094, 2008.
5. Gross M, Nepomuceno E and Agus DB. Application of proteomics in prostate cancer. Figg WD, Chau CH and Small EJ, eds. In Drug Management of Prostate Cancer, 1st Edition, 2008.

Books

1. **Agus DB**: Interleukin-2: a molecular, cellular and clinical study. Thesis, 293 p., Princeton University, 1987.
2. **Agus DB**: The End of Illness. Simon & Schuster (Free Press), New York, NY, 333 p., 2012.
3. **Agus DB**: A Short Guide to a Long Life. Simon & Schuster, 191 p., New York, NY, 2014.
4. **Agus DB**: The Lucky Years: How to Thrive in the Brave New World of Health. Simon & Schuster, 288 p., New York, NY, 2016.